BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech

Biopharma Insights


How AI Is Transforming Medicinal Chemistry: …

How AI Is Transforming Medicinal Chemistry: From Discovery to Manufacturing

Aug. 21, 2025   by Andrii Buvailo, PhD     Articles
In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic …
Continue ›››
"AI Scientists" - New Collaborators for …

"AI Scientists" - New Collaborators for Rare Disease Research?

July 28, 2025   by Louise von Stechow     Business Intelligence
In the quest to understand and treat the over 6,000 rare diseases, researchers encounter a number of limitations – in …
Continue ›››
What are Foundation Models in Biology …

What are Foundation Models in Biology and Healthcare?

Sept. 21, 2024   by BiopharmaTrend     Articles
Content: History of AI in the Context of Foundation Models The Technology Stack Behind Foundation Models The Paradigm Shift in …
Continue ›››
Into the Unknown — How Artificial …

Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome

June 30, 2025   by Louise von Stechow     Business Intelligence
With DeepMind’s release of AlphaGenome—a deep learning model that can predict the relevance of variants in both coding and non-coding …
Continue ›››
Beyond Legacy Tools: Defining Modern AI …

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

April 15, 2025   by Andrii Buvailo, PhD, Oleg Kucheriavyi, PhD     Business Intelligence
In this report: Intro: The New Framework “AI Drug Discovery” is About Holism "AI Drug Discovery" is About Building Software …
Continue ›››
AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis

AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis

May 30, 2025   by Adele Ruder, Alexander Hustinx, Louise von Stechow     Business Intelligence
Rare diseases, which affect more than 300 million people worldwide, are often difficult to diagnose. Many patients wait five years …
Continue ›››
How AI, Graphs, and GraphRAG Are …

How AI, Graphs, and GraphRAG Are Set to Revolutionize Alzheimer's Gene Research and Treatment

May 3, 2025   by Dominik Tomicevic     Articles
An estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s. Without major medical breakthroughs, that number is …
Continue ›››
Novotech Report: Over 800 Global IPF …

Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific

April 24, 2025   by BiopharmaTrend     Business Intelligence
Novotech CRO has released a global market analysis focused on the clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF), identifying …
Continue ›››
Report: Nearly 80% of Life Sciences …

Report: Nearly 80% of Life Sciences Leaders Considering Virtual Models for Observational Research

March 24, 2025   by BiopharmaTrend     Business Intelligence
A new industry report from PicnicHealth reveals that nearly 80% of life sciences leaders are open to using virtual models …
Continue ›››

AI in Drug Safety: From Concept to Reality, The Industry's Path Forward

Feb. 25, 2025   by Dr. Karthik Muthusamy     Business Intelligence
Pharmaceutical companies are dealing with an unprecedented volume of safety data with artificial intelligence moving from theoretical applications to practical …
Continue ›››
Combination Therapies May Be the Future …

Combination Therapies May Be the Future of Oncology – How Can We Navigate Development Challenges Today?

Feb. 9, 2025   by Andreas Dreps, Bea Mann, PhD     Business Intelligence
The field of oncology is experiencing a proliferation of cancer therapies. In 2024 alone, the U.S. Food and Drug Administration …
Continue ›››
What CROs Cite as Their Top …

What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025

Jan. 10, 2025   by Megan Deegan     Business Intelligence
In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech …
Continue ›››
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
#advertisement
Pharma Complience Management: A UK/EU Guide

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.